Lexicon Pharmaceuticals(LXRX) - 2025 Q3 - Quarterly Results

Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES R&D UPDATES FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 ...